1
Stroke Reduction1-3
Avoiding aortic manipulation to protect the neurologic outcome.
OPCABAnaortic TechniquesNo-Touch Aorta
In the news — CVD Burden
Nearly 6 in 10 women projected to have cardiovascular disease by 2050
Source: American Hospital Association summarizing an American Heart Association scientific statement (2026)
Section 1 — The Stakes
CVD Burden
Cardiovascular disease (CVD) remains the leading cause of death in the United States. The figures below frame the clinical and economic problem AUREUSCV™ is built to address.
1 in 3U.S. deaths
Share of all U.S. deaths attributable to CVD
1 in 20Adults 20+
U.S. adults age 20 and older living with CAD
Major modifiable risk factors
The population-level drivers of coronary artery disease (CAD) are widespread and, critically, modifiable — which is precisely why surgical revascularization volume is not projected to fall.
Hypertension≈47%
Elevated weight≈70%
Obesity≈42%
Type 2 diabetes or prediabetes>57%
Sources ,
Public Health Burden(U.S. Mortality)
Cardiovascular Disease (CVD),
919,032
U.S. deaths (2023)
- ≈ 1 in every 3 (33%) deaths
- Leading U.S. cause of death
Coronary Artery Disease (CAD) / Coronary Heart Disease (CHD)
371,506
deaths (2022)
- Most common heart disease type
- Largest contributor within heart disease
Prevalence and RiskWho is Affected?
Adults CAD Prevalence
1 in 20
U.S. adults age 20 and older have CAD
- ≈ 5% of the adult population
Major Modifiable Risk Factors,
47%
of U.S. adults have hypertension
- Obesity & elevated weight — about 42% & 70%, respectively
- Type 2 diabetes or prediabetes — more than half (> 57%) of U.S. adults affected
Economic & Health SystemBurden
Annual CVD & Stroke Costs
418B
average annual direct/indirect U.S. costs
- CVD and stroke combined, in U.S. dollars
Medicare Burden, Older Adults
40%+
of Medicare beneficiaries aged 65+ have at least one heart condition
- CVD is one of the most prevalent and costly chronic conditions in Medicare beneficiaries
Not Medical Advice / For Information Only.
Statistics reflect sources cited and may be updated as new data become available.
- 1Docter-Loeb H. Heart disease remains the top cause of death in the U.S. The Washington Post. February 24, 2025. Accessed June 17, 2026. View source ↗
- 2American Heart Association. Heart disease remains leading cause of death as key health risk factors continue to rise. News release. January 26, 2025. Accessed June 17, 2026. View source ↗
- 3Centers for Disease Control and Prevention (CDC). Heart disease facts. October 24, 2024. Accessed June 17, 2026. View source ↗
- 4Ohio Cardiovascular and Diabetes Health Collaborative (Cardi-OH). Current 51 — Heart disease remains leading cause of death in U.S. June 29, 2025. Accessed June 17, 2026. View source ↗
- 5Martin SS, Aday AW, Allen NB, et al. 2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2025;151(8):e41-e660. doi:10.1161/CIR.0000000000001303 View source ↗
- 6Kazi DS, Elkind MSV, Deutsch A, et al. Forecasting the economic burden of cardiovascular disease and stroke in the United States through 2050: a presidential advisory from the American Heart Association. Circulation. 2024;150(4):e89-e101. doi:10.1161/CIR.0000000000001258 View source ↗
- 7Office of the Assistant Secretary for Planning and Evaluation (ASPE). Report to Congress — the burden of cardiovascular disease in the United States: patterns and barriers to care. U.S. Department of Health and Human Services. September 11, 2024. Accessed June 17, 2026. View source ↗
In the news — CABG Surgery
Late-Breaking STS Study: Off-Pump CABG by Experienced Surgeons Cuts Perioperative Complications With Comparable Long-Term Survival
Source: The Society of Thoracic Surgeons press release (2026)
Section 2 — The Solution
CABG Surgery
Coronary artery bypass graft (CABG) surgery is the gold standard in coronary revascularization. Enabling technologies eliminate procedural barriers so cardiothoracic surgeons can tailor the optimal approach for every patient.
ONCAB
OPCAB
RA-CABG
TECAB
2
Multi-Arterial Revascularization4,5
Arterial conduit strategies associated with long-term survival.
BITASITA + RABITA + RA
3
Less-Invasive6-8
Smaller incision, preserved sternal integrity, faster recovery.
MIDCABThoraCABMICS CABG
4
Long-Term Patency9,10
Conduit selection as the determinant of durable revascularization.
LIMA AdvantageGraft DurabilityRA vs. SVG
Selected independent literature illustrating current evidence trends in CABG surgery; not derived from AUREUSCV™ clinical trials.
Sources are provided for educational context and do not constitute promotion of any specific product or procedure.
- 1Puskas JD, Williams WH, O'Donnell R, et al. Off-pump and on-pump coronary artery bypass grafting are associated with similar graft patency, myocardial ischemia, and freedom from reintervention: long-term follow-up of a randomized trial. Ann Thorac Surg. 2011;91(6):1836-1843. doi:10.1016/j.athoracsur.2010.12.043 View source ↗
- 2Ushioda R, Hirofuji A, Yoongtong D, et al. Assessing the benefits of anaortic off-pump coronary artery bypass grafting. Front Cardiovasc Med. 2024;11:01-09. doi:10.3389/fcvm.2024.1393921 View source ↗
- 3Plonek T, Mendyka D, Halfwerk FR. No-touch aorta off-pump LIMA-radial artery Y-graft CABG as a safe strategy for all-comers: long-term survival. J Clin Med. 2025;14(14):4878. doi:10.3390/jcm14144878 View source ↗
- 4Schwann TA, Habib RH, Gaudino MF, et al. Comparative effectiveness of multi-arterial coronary artery bypass grafting: BITA, SITA + RA, BITA + RA. Presented at: Society of Thoracic Surgeons 2026 Annual Meeting; January 29–February 1, 2026; New Orleans, LA. View source ↗
- 5Momin A, Ranjan R, Valencia O, et al. Long term survival benefits of different conduits used in coronary artery bypass graft surgery — a single institutional practice over 20 years. J Multidiscip Healthc. 2024;17:1505-1512. doi:10.2147/JMDH.S461567 View source ↗
- 6Cremer J, Schoettler J, Thiem A, Grothusen C, Hoffmann G. The MIDCAB approach in its various dimensions. HSR Proc Intensive Care Cardiovasc Anesth. 2011;3(4):249-253. View source ↗
- 7Ishikawa N, Watanabe G, Tomita S, et al. Robot-assisted minimally invasive direct coronary artery bypass grafting: ThoraCAB. Circ J. 2014;78(2):399-402. doi:10.1253/circj.cj-13-1115 View source ↗
- 8Une D, Lapierre H, Sohmer B, Rai V, Ruel M. Can minimally invasive coronary artery bypass grafting be initiated and practiced safely?: a learning curve analysis. Innov Technol Tech Cardiothorac Vasc Surg. 2013;8(6):403-409. doi:10.1097/IMI.0000000000000019 View source ↗
- 9Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med. 1986;314(1):1-6. doi:10.1056/NEJM198601023140101 View source ↗
- 10Gaudino M, Benedetto U, Fremes S, et al. Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery. N Engl J Med. 2018;378(22):2069-2077. doi:10.1056/NEJMoa1716026 View source ↗
Section 3 — The Company
Company
Aureus Cardiovascular (AUREUSCV™) is a medical device company modernizing enabling technologies for coronary artery bypass grafting (CABG) and minimally invasive cardiac surgery (MICS) to improve neurologic safety and long-term graft performance for patients with coronary artery disease (CAD), the leading form of cardiovascular disease (CVD).
Strategic Business Development Partner
NEFEDC ↗AUREUSCV™ operates under quality, risk, and data governance practices aligned with ISO 13485:2016, ISO 14971:2019, and FDA Quality Management System Regulation (QMSR), effective February 2, 2026.
3.1
Patents
AUREUSCV™ enabling technologies, including its platforms, systems, and related methods, as well as future improvements, may be covered by one or more U.S. and international patents, patent applications, and other intellectual property rights. This notice is intended to satisfy applicable virtual patent marking provisions.
For publicly available information on issued and pending U.S. patents and applications, interested parties may refer to the United States Patent and Trademark Office (USPTO) Patent Public Search database.
AUREUSCV™, IRIS PROXIMAL ANASTOMOSIS SYSTEM™, U-CLIP™, and C-PORT™ are trademarks of Aureus Cardiovascular, Inc.
3.2
Investors
AUREUSCV™ is revitalizing enabling technologies for cardiovascular surgery, focusing on CVD burden — the needs of the patient — and CABG procedures — the needs of the cardiothoracic surgeon — with the sole aim of optimizing patient outcomes.
Our SPAR operating model integrates clinically proven MedTech with next-generation digital engineering tools embedded in ISO and FDA-aligned quality and risk workflows to create enduring value over traditional regulatory pathways, the adoption curve, and the proficiency required for new surgical technologies and procedures.
We welcome interest from long-horizon, thesis-driven permanent capital investors across family offices, evergreen funds, permanent capital vehicles, specialty private equity, and structured credit. To explore strategic alignment, please use our Contact form, select ‘Investor inquiry,’ and provide a brief 3–4 line overview of your structure, investment horizon, and focus areas.
Forward-looking statements: Certain statements on this page may be forward-looking and are subject to risks and uncertainties; actual results may differ materially.
Stage & milestones: acquisition and revitalization of previously validated CABG enabling technologies; upcoming milestones focus on design transfer, verification/validation, and regulatory re-entry under modernized standards.
3.3
Careers
AUREUSCV™ is revitalizing enabling technologies for cardiovascular surgery procedures, bringing together mission-driven engineers, next-generation digital engineering tools, and rigorous medical device development.
If you are passionate about optimizing CVD patients’ outcomes and modernizing the tools cardiothoracic surgeons need, please use our Contact form, select ‘Other,’ and submit a brief 3–4 line note in the Message box on who you are, your core discipline (e.g., R&D, Mfg., QARA), and why this work matters to you.
Section 4 — The Close
Contact Us
Interested in strategic partnering, investment diligence, or clinical collaboration? Share a few details and our team will follow up.
Direct
[email protected]7751 Belfort Pkwy, Ste 200Jacksonville, FL 32256-6933
*We generally respond within 2–3 business days.